Introducing AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL)

PanOptix is a revolutionary trifocal IOL for patients undergoing cataract surgery.

It is the first and only trifocal lens approved by the U.S. Food and Drug Administration (FDA) and available in the U.S.

20/20 near, intermediate and distance vision is now possible with PanOptix.1*

*Based on mean value of binocular defocus from curve at near, intermediate and distance at 6 months. Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.

PanOptix is built on Alcon’s proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.

Clinically-Proven Benefits

The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S. With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision.1

Results from the 129 subjects implanted with PanOptix in the prospective and parallel-group clinical study revealed that:

- More than 99 percent of PanOptix patients in the FDA clinical study said they would choose the same lens again.1
- 98 percent of PanOptix patients would recommend the PanOptix IOL to their friends and family.1
- 80.5 percent of PanOptix patients reported in a survey that they never needed to wear glasses after surgery.1*

*Survey question asked, “how often have you needed glasses within the past 7 days.”
AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) with ENLIGHTEN™ Optical Technology

**DESCRIPTION:**

The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide.

With a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decrease in ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog, or in a dimly lit room after surgery as compared to before surgery. Further, a toric IOL corrects astigmatism only when it is placed in the correct position in the eye. There is a possibility that the toric IOL could be placed incorrectly or could move within the eye. If the toric lens is not positioned correctly following surgery, the change in your astigmatism correction by the IOL, along with any necessary correction with glasses, may cause visual distortions. If the lens rotates in your eye, you may need additional surgery to reposition or replace the IOL.

1. AcrySof® IQ PanOptix® Directions For Use.
5. Compared to AcrySof® monofocal IOL.

**How Does PanOptix Work?**

PanOptix utilizes Alcon's proprietary, non-apodized ENLIGHTEN (Ehanced LIGHT ENergy) Optical Technology, which optimizes intermediate vision without compromising on near and distance.  

Alcon created this patented technology as a solution to improve on the limitations of traditional trifocal IOLs, which typically have an intermediate focal point that isn't comfortable for most patients.  

PanOptix offers an excellent intermediate vision range and is designed to improve vision after cataract surgery for today's active lifestyles, from viewing mobile devices to high-quality distance vision in a range of lighting conditions.

PanOptix is already one of the leading presbyopia-mitigating IOLs in more than 70 countries, where the response from patients has been overwhelmingly positive. PanOptix is now available in the U.S. to cataract patients seeking exceptional vision while significantly reducing the need for glasses after surgery.

**Did You Know? More than 4 million cataract surgeries are performed each year in the U.S., a number that is projected to increase by more than 16 percent by the end of 2024.**